C
C.J. Glueck
Researcher at University of Los Andes
Publications - 15
Citations - 577
C.J. Glueck is an academic researcher from University of Los Andes. The author has contributed to research in topics: Triglyceride & Lipoprotein. The author has an hindex of 11, co-authored 15 publications receiving 567 citations. Previous affiliations of C.J. Glueck include Jewish Hospital & University of Cincinnati Academic Health Center.
Papers
More filters
Journal ArticleDOI
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.
TL;DR: Metformin decreases Izero in hyperinsulinemic PCOS patients, reverses the hyperinsulinemia-driven endocrinopathy, decreases PAI-1, and decreases Lp(a), and should thus reduce the increased risk of atherothrombosis in PCOS.
Journal ArticleDOI
Phytosterols in aortic tissue in adults and infants.
TL;DR: Relationships between aortic tissue phytosterols and cholesterol in five adults, five infants, two neonates, and one 30 week abortus were studied and their relationship to deposition of cholesterol in atheromatous and in normal aorti tissues remains to be elucidated.
Journal ArticleDOI
Hypertriglyceridemia and hypoalphalipoproteinemia in azoospermic and oligospermic young men: relationships of endogenous testosterone to triglyceride and high density lipoprotein cholesterol metabolism.
TL;DR: Examination of potential relationships between endogenous testosterone, luteinizing hormone, follicle stimulating hormone, lipids-lipoproteins, and lipoprotein lipases found that fertile men had much higher fasting plasma triglyceride levels than did normal controls.
Journal ArticleDOI
Effect of physical training on lipids, lipoproteins, apolipoproteins, lipases, and endogenous sex hormones in men with premature myocardial infarction.
TL;DR: A modest, achievable exercise program can have significant cardiovascular benefit for men after myocardial infarction by ameliorating their hyperestrogenemia, reducing TC and LDLC, improving the TC to HDLC ratio, and elevating HDLC and apo A2.
Journal Article
Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein[a].
TL;DR: It is speculated that the potential cardioprotective effect of estrogen-progestin therapy in postmenopausal women may be mediated through lowering Lp(a) as well as raising HDLC and apolipoprotein A1, lowering apoledipoprotein B and blood pressure, and decreasing insulin resistance.